Viking Therapeutics is at a pivotal moment as it moves VK2735, its lead obesity treatment, into Phase 3 trials following the completion of patient enrollment in the VANQUISH-2 trial. Analysts are bullish, projecting stock price targets between $107 and $125, boosted by VK2735's potential efficacy as a dual GLP-1/GIP agonist. While the company faces competitive pressures and past setbacks, it is positioned as a prime acquisition target, with expectations for significant market impact and billions in potential revenue pending FDA approval.
“Here's what might happen. Viking Therapeutics could deliver efficacy on par with the current leading weight-loss medicine, Eli Lilly's Zepbound, also a dual GLP-1/GIP agonist.”
“My personal opinion is $VKTX will show best in class oral treatment for obesity as a maintenance regimen as compared to any other drug or drugs on the market.”
“$VKTX stock has been under pressure for last few years on the notion that Small molecules has better advantages vs peptides is slowing fading.”
“Dual agonist Peptides still remains the best bet for obesity and believe $VKTX results will show that when results come.”
“$VKTX remains top bullish biotech position in the obesity space.”
“$VKTX is not just a sleeping pill, especially considering Lilly paid $7B just for a sleeping pill. $7B is a drop in the ocean for Lilly.”
“@HarpA70278288 @bioinvestor24 @JCanNuSH You are wrong if you think Brian would even respond to a $VKTX buyout offer for $30B”
“$VKTX maintenance study is so relevant. Viking CEO outsmarted all others with this study.”
“$VKTX once approved will capture a good portion of obesity sales in both subq and oral forms and we are looking at Billions of dollars in revenue”
“$VKTX with or without an acquisition, shareholders will be rewarded as we get closer to phase three results and fda approval.”
“$VKTX CEO is trusted by other pharma. They know he is not pumping a stock. Once you realize that Viking might be sold for $70 billion you understand the CEO.”
“The maintenance trial will show up Viking's adherence advantages which is the new priority for the FDA.”